Recent research papers

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2000 | 1999 | 1998 | 1997

  1. Foldvari, M. (2020) Preface: Nano-Enabled Medical Applications. Nanomedicine’s Most Cited. Vol. 2., L. Balogh (Editor) Jenny Stanford Publishing (in press)
     
  2. Chen D.W. and Foldvari, M. (2017). A versatile in vitro bioassay for the screening of neurotrophic factor gene therapy systems to combat blindness. Atlas of Science. https://atlasofscience.org/a-versatile-in-vitro-bioassay-for-the-screening-of-neurotrophic-factor-genetherapy- systems-to-combat-blindness/
  3. Chen DW, Pauloff K and Foldvari M. (2018). Three-dimensional co-culture bioassay for screening of retinal gene delivery systems. Methods in Molecular Biology (MiMB) series; In: “Retinal Gene Therapy: Methods and Protocols” ed. Wijnholds J. (Springer) 1715:79-88.
     
  4. Calderon-Nieva D, Bandara-Goonewardene K, Gomis S, Foldvari M. (2017) Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals. Drug Deliv Transl Res DOI 10.1007/s13346-017-0400-9
  5. Foldvari M, Bagonluri M. (2017) Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Chapter 19, In: Nanomedicine in cancer. L.P. Balogh (ed.) Pan Stanford Publishing, pp 487-522.
     
  6. Foldvari M, Bagonluri M. (2017) Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Chapter 20, In: Nanomedicine in cancer. L.P. Balogh (ed.) Pan Stanford Publishing, pp 523-548.
     
  7. Foldvari M. and Kumar P. (2017) Perspectives on dermal delivery of macromolecular drugs. In: Percutaneous penetration enhancers. Drug penetration into/through the skin. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer-Verlag Berlin Heidelberg DOI 10.1007/978-3-662-53270-6_21
  8. Foldvari M and Chen, DW. (2016) The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy. Invited Review, Neural Regen. Res.11:875-877.
  9. Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee, A. (2016) Non-viral gene therapy: gains and challenges of non-invasive administration methods. Invited review for the North American Special Issue; J. Control. Rel.  240:165-190.  doi:10.1016/j.jconrel.2015.12.012

  10. Bottini M and Foldvari M (2016) Targeted nanosystems as therapeutic and diagnostic tools: The beautiful voyage of nanomedicine. Nanomedicine: NMB, DOI: http://dx.doi.org/10.1016/j.nano.2015.12.358

  11. Gharagozlo, M., Majewski S. and Foldvari M. (2015) Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction. Nanomedicine: NBM 11:1003-18.
  12. Nafissi N. and Foldvari M. (2016) Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8:240-254. DOI: 10.1002/wnan.1361
  13. Nafissi N. and Foldvari M. (2015) Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front. Neurosci. 9:355.
  14. Foldvari M. and Kumar P. (2016) Permeation enhancement by molecular organization switching (MOS): Biphasic vesicles for the cutaneous delivery of proteins. In: Percutaneous penetration enhancers. Chemical Methods in Penetration Enhancement. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer pp. 309-318. http://dx.doi.org/10.1007/978-3-662-47862-2_20
  15. Elsabahy M, Loureiro MJ, Foldvari M. (2015) Application of nanotechnology in non-invasive topical gene therapy. In: Clinical Nanomedicine. Ed.: R. Bawa, G. Audette, Pan Stanford Press
  16. Foldvari M. and Rafiee A. (2015) Perspectives on using nanoscale delivery systems in dermatological treatment. Curr. Derm. Rep. 4:1-7.
  17. Foldvari M. (2014) Non-invasive ocular drug delivery: Potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma.  J. Glaucoma 23:8, Suppl 1, S80-82.
  18. Foldvari M (2014) Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedicine Biotherapeutic Discov 4: e135. doi: 10.4172/2155-983X.1000e135
  19. Gendelman HE, Balogh LP, Bawa R., Bradbury M, Chang EH, Chiu W, Farokhzad O, Foldvari M, Lanza G, Wang K. (2014) The 4th Annual Meeting of the American Society for Nanomedicine. J. Neuroimmune Pharmacol. 9 (Suppl1) S1-3.
  20. Foldvari M., Gharagozloo M. and Li C. (2014) Nanoparticles for dermal and transdermal delivery: Permeation pathways and applications. In: Torchilin, V. (ed.) Frontiers in nanobiomedical research. World Scientific Publishing, Volume 2, Chapter 7, pp 231-260. doi: 10.1142/9789814520652_0024 
  21. Narsineni, and Foldvari M. (2020) Dicationic amino substituted gemini surfactants and their nanoplexes:  Improved synthesis and characterization of transfection efficiency and corneal penetration in vitro. Pharm Res 37:144.
     
  22. GunawardanaT, Ahmed KA, Goonewardene K,Popowich S, Kurukulasuriya S,Karunarathana R, Ayalew, LE, Gupta A, Chow-Lockerbie B, Foldvari M,Tikoo S, Willson P and Gomis S. (2020) CpG-ODN Induces a Dose-Dependent Enrichment of Immunological Niches in the Spleen and Lungs of Neonatal Chicks That Correlates with the Protective Immunity against Escherichia coli. J Immunol Res 2020, Article ID 2704728, 15 pages https://doi.org/10.1155/2020/2704728
  23. Taheri-Araghi S., Chen D.W., Kohandel M., Sivaloganathan S., and Foldvari M. (2019) Tuning effects of cationic to anionic charge ratio and helper lipids on non-viral gene delivery system: a theoretical and experimental study on gemini nanoparticles. Nanoscale 11:1037-1046.
  24. GunawardanaT, Ahmed KA, Goonewardene K,Popowich S, Kurukulasuriya S,Karunarathana R, Gupta A, Chow-Lockerbie B, Foldvari M,Tikoo S, Willson P and Gomis S. (2019) Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infection. Sci. Reports, 9:1-14.
  25. Chen DW, Narsineni L and Foldvari M. (2018) Multipotent stem cell-derived retinal ganglion cells in 3D culture as tools for neurotrophic factor gene delivery system development. Nanomedicine: NBM, 21:102045.
     
  26. Miki C, Dewitt-Orr S., Foldvari, M., Moore, M. (2018) Anti-aging properties of phytoglycogen. HPC Today, 13(2):16-18.
  27. Chen DW and Foldvari M. (2018) Retinal multipotent stem cell derived “MiEye” spheroid 3D culture model for preclinical screening of non-viral gene delivery systems. Precision Nanomedicine 1(2):106-123 DOI:10.29016/180711.1
  28. Chen DW, Pauloff K. and Foldvari M. (2018) Three-dimensional co-culture bioassay for screening of retinal gene delivery systems. Methods Mol. Biol. 1715:79-88. doi: 10.1007/978-1-4939-7522-8_6.
  29. Goonewardene K, Popowich S, Gunawardana, T, Gupta A, Kurukulasuriya S, Karunarathna  R, Chow-Lockerbie B, Ahmed KA, Tikoo S, Foldvari M, Willson P and Gomis S.. (2017) Intrapulmonary delivery of CpG-ODN microdroplets provides protection against Escherichia coli septicemia in neonatal broiler chickens. Avian Diseases 61 (4), 503-511.
  30. Chen DW and Foldvari M. (2016) In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment. Drug Deliv. Transl. Res. 6:676-685. doi:10.1007/s13346-016-0324-9
  31. Gharagozloo MRafiee AChen DWFoldvari M. (2015) A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: an implication for cell membrane nanoporation. J. Nanobiotechnol. 13:62.
  32. Cunha VR,   Guilherme VA,  de Paula E,  de Araujo DR, Silva RO, Medeiros J VR, Leite JR, Petersen PA, Foldvari M, Petrilli HM, Constantino VR. (2016)Delivery system for mefenamic acid based on the nanocarrier Layered Double Hydroxide: physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential. Mater. Sci. Eng. C Mater. Biol. Appl. 58:629-38. 
  33. Huzil JT, Saliaj E, Ivanova M, Gharagozloo M, Loureiro JM, Lamprecht  C, Korinek A, Chen DW, Foldvari M. (2015) Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes. Future Sci. OA FSO17
  34. Dong C, Badea I, Poorghorban M, Verrall R, Foldvari M. (2015) Impact of phospholipids on plasmid packaging and toxicity of gemini nanoparticles. J. Materials Chem. B, 3: 8806-8822.
  35. Foldvari M. (2015) Membrane fusion intermediates captured in liposomal dispersion by freeze-fracturing. F1000 Research 2015, 4:4 (doi: 10.12688/ f1000research.6003.1)
  36. Gunawardana T, Foldvari, M, Zachar T, Popowich S, Chow-Lockerbie B, Ivanova M, Tikoo S, Kurukulasuriya S, Willson P and Gomis S.. (2015) Protection of neonatal broiler chickens following in ovo injection of oligodeoxynucleotides containing CpG motifs (CpG-ODN) formulated with carbon nanotubes or liposomes. Avian Dis. 59:31-37.
  37. Alqawlaq S, Sivak J, Huzil JT, Ivanova MV, Flanagan, J, Beazely, M, Foldvari M. (2014) Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration for glaucoma gene therapy.  Nanomedicine: NBM 10:1637-1647.
  38. Nafissi N, Alqawlaq S, Foldvari M, Lee E, Spagnuolo P, Slavcev R. (2014) Ministring DNA: Superior gene delivery vector. Mol. Ther. Nucleic Acids 3, e165 doi:10.1038/mtna.2014.16

2013

Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Huzil JT, Foldvari M. (2013) Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm 10(6):2248-60.

King M, Kumar P, Michel D, Batta R, Foldvari M. (2013) In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm 84(3):532-9.

Elsabahy M, Foldvari M. (2013) Needle-free gene delivery through the skin: an overview of recent strategies. Curr Pharm Des 19(41):7301-15.

2012:

Alqawlaq, S, Huzil, JT, Ivanova, MV and Foldvari, M. (2012) Non-viral gene-therapy of glaucoma: Challenges in neuronal nanomedicine development. Nanomedicine (Future Medicine) 7(7):1067-1083.

Foldvari, M and Kumar, P. (2012) Recent progress in the application of nanotechnology for the prevention and treatment of human papillomavirus infection. Therapeutic Delivery 3(8):1005-1017.

Donkuru M, Wettig SD, Verrall R, Badea I, Foldvari M. (2012) Designing pH-sensitive gemini nanoparticles for non-viral gene delivery into keratinocytes. J Mater Chem 22:6232-6244.

Badea I, Virtanen C, Verrall R, Rosenberg A, Foldvari M. (2012) Topical interferon-γ gene therapy using gemini (dicationic) nanoparticles improves pathophysiological markers of scleroderma in Tsk1/+ mice. Gene Ther 19: 978-987.

Ivanova M, Lamprecht C, Loureiro MJ, Huzil T, Foldvari M. (2012) Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. International Journal of Nanomedicine 7:403-415.

2011:

Huzil T, Sivaloganathan S, Kohandel M , Foldvari M. (2011) Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3:449–462.

Lamprecht C, Huzil T, Ivanova M, Foldvari M. (2011) Non-Covalent Functionalization of Carbon Nanotubes with Surfactants for Pharmaceutical Applications A Critical Mini-Review. Drug Delivery Letters 1:45-57.

Badea I, Shaterian, N. , Foldvari M. (2011) Topical Gene Delivery in Mice Using Gemini Surfactant - Lipid Nanoparticles With and Without Tape Electrode Electroporation. Drug Delivery Letters 1:62-66.

Foldvari M, Elsabahy M. (2011) Editorial Hot Topic: Nanotechnology Enables Superior Medical Therapies. Current Drug Delivery 8:225-226.

Elsabahy M, Nazarali A, Foldvari M. (2011) Non-Viral Nucleic Acid Delivery: Key Challenges and Future Directions. Current Drug Delivery 8:235-244.

Singh J, Yang P, Michel D, Verrall RE, Foldvari M, Badea I. (2011) Amino Acid-Substituted Gemini Surfactant-Based Nanoparticles as Safe and Versatile Gene Delivery Agents. Current Drug Delivery 8:299-306.

Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah Z, Gaspar K, Hull P, Shear NH. (2011) Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Current Drug Delivery 8:307-319.

2010:

Donkuru M, Badea I, Wettig SD, Verrall RE, Elsabahy M, Foldvari M. (2010) Advancing non-viral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Future Medicine) 5:1103-1127.

Yang P, Singh J, Wettig SD, Foldvari M, Verrall RE, Badea I. (2010) Enhanced gene expression in epithelial cells transfected with amino-acid substituted gemini nanoparticles. Eur J Pharm Biopharm 75:311-320.

Foldvari M. (2010) Formulating nanomedicines: focus on carbon nanotubes as novel nanoexcipients. Key Eng Mat 441:53-74.

Foldvari M, Badea I, Wettig SD, Baboolal D, Kumar P, Creagh AL, Haynes CA. (2010) Topical delivery of interpheron alpha by biphasic vesicles: evidence for a novel nanopathway across the stratum corneum. Mol Pharmaceutics 7:751-762.

2009:

Badea I, Babiuk S, Babiuk L, Foldvari M. (2009) Gemini nanoparticles as co-delivery systems for antigen-CpG oligodeoxynucleotide adjuvant combination. Int J Biomed Nanosci Nanotech1:290-307.

Badea I, Taylor M, Rosenberg A, Foldvari M. (2009) Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheomatology 48:213-221.

Taghavi A, Allan B, Mutviri G, Foldvari M, Van Kessel A, Willson P, Babiuk L, Potter A, Gomis S. (2009) Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Del 6:76-82.

Kumar P, Batta R, LaBine G, Shen J, Gaspar K, Docherty J, Foldvari M. (2009) Stabilization of interpheron alpha-2b in a topical cream. Pharm Technol 33:80-86.

2008:

Foldvari M, Bagonluri M. (2008) Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine 4:173-182.

Foldvari M, Bagonluri M. (2008) Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine 4:183-200.

2007:

Wettig SD, Badea I, Donkuru, M, Verrall RE, Foldvari M. (2007) Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles. J Gene Med 9(8):649-658.

Wang C, Li X, Wettig SD, Badea I, Foldvari M, Verrall RE. (2007) Investigation of complexes formed by interaction of cationic gemini surfactants with deoxyribonucleic acid. Phys Chem Chem Phys 9:1616-1628.

Wettig SD, Wang C, Verrall RE, Foldvari M. (2007) Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys Chem Chem Phys 9:871-877 (appears on front cover).

Wang C, Wettig SD, Foldvari M, Verrall RE. (2007) Synthesis, characterization and use of asymmetric pyrenyl-gemini surfactants as emissive components in DNA-lipoplex systems. Langmuir 23:8995-9001.

Badea I, Wettig SD, Verrall RE, Foldvari M. (2007) Topical non-invasive gene delivery using gemini nanoparticles in interferon-γ-deficient mice. Eur J Pharm Biopharm 65(3):414-422.

2006:

Foldvari M, Wettig SD, Badea I, Verrall RE, Bagonluri M. (2006) Dicationic gemini surfactant gene delivery complexes contain cubic-lamellar mixed polymorphic phase. Nanotech 2:400-403.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006) Biphasic lipid vesicles as subcutaneous delivery systems for protein antigens and CpG oligonucleotides. Curr Drug Del 3:129-135.

Foldvari M. (2006) Topical non-invasive delivery technologies for the delivery of genetic material. (Editorial) Curr Drug Deliv 3(1):1.

Foldvari M, Babiuk S, and Badea I. (2006) DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv 3:17-28.

Wei C, Lyubchenko YL, Ghandehari H, Hanes J, Stebe KJ, Mao HQ, Haynie DT, Tomalia DA, Foldvari M, Monteiro-Riviere N, Simeonova P, Nie S, Mori H, Gilbert S, Needham D. (2006) New technology and clinical applications of nanomedicine: Highlights of the Second Annual Meeting of the American Academy of Nanomedicine (Part I). Nanomedicine 2:253-263.

Cui Z, Dierling A, Foldvari M. (2006) Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv 3:29-35.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006). Biphasic lipid vesicles as subcutaneous delivery systems for protein antigens and CpG oligonucleotides. Curr Drug Del 3:129-135.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006). Biphasic lipid vesicles as subcutaneous delivery systems for protein antigens and CpG oligonucleotides. Curr Drug Del 3:129-135.

Foldvari M, Kumar P, King M, Batta R, Michel D, Badea I, Wloch M. (2006) Gene delivery into human skin in vitro using biphasic lipid vesicles. Curr Drug Deliv 3:89-96.

Foldvari M, Badea I, Wettig SD, Verrall RE, Bagonluri M. (2006) Structural characterization of novel gemini non-viral DNA delivery systems for cutaneous gene therapy (PDF). J Exp Nanosci 1:165-176.

2005:

Foldvari M, Badea I, Wettig S, Verrall R and Bagonluri M. (2005) Structural characterization of novel micro- and nano-scale non-viral DNA delivery systems for cutaneous gene therapy. Nanotech 1:128-131.

Alcón V, Baca-Estrada M, Vega-López M, Willson P, Babiuk LA, Kumar P, Hecker R and Foldvari M. (2005). Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs (PDF). AAPS Journal 7(3) Article 57:E566-571.

Alcón VL, Baca-Estrada M, Vega-López MA, Willson P, Babiuk LA, Kumar P and Foldvari M. (2005). Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. J Pharm Pharmacol 57:955-962.

Alcón VL, Baca-Estrada M, Vega-López MA, Willson P, Babiuk LA, Kumar P and Foldvari M. (2005). Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. J Pharm Pharmacol 57:955-962.

Badea I, Verrall R, Baca-Estrada M, Tikoo S, Rosenberg A, Kumar P and Foldvari M. (2005) In vivo cutaneous interferon-γ gene delivery using novel dicationic (gemini) surfactant–plasmid complexes. J Gene Med 7:1200-1214.

Li X, Wettig SD, Wang C, Foldvari M and Verrall RE. (2005) Synthesis and solution properties of gemini surfactants containing oleyl chains. Phys Chem Chem Phys 7:3172-3178.

2004:

Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. (2004). Biphasic lipid vesicles (Biphasix™) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv 1:9-15.

Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. (2004). Biphasic lipid vesicles (Biphasix™) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv 1:9-15.

2003:

Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L. (2003). Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin (PDF). Mol Ther 8:992-998.

Alcón VL, Foldvari M, Snider M, Willson P, Gomis S, Hecker R, Babiuk LA, Baca-Estrada ME. (2003). Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix™). Vaccine 21:1811-1814.

Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L. (2003). Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin (PDF). Mol Ther 8:992-998.

King MJ, Michel D, Foldvari M. (2003) Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol 55:1339-1344.

2002:

Jaafari MR, Foldvari M. (2002). Targeting of liposomes to human keratinocytes through adhesive peptides from immunoglobulin domains in the presence of IFN-gamma. Drug Deliv 9:1-9.

Jaafari MR, Foldvari M. (2002). Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains. J Pharm Sci 91:396-404.

Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. (2002). The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107:69-76.

Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. (2002). The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology 107:69-76.

Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. (2002) Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol 54:1609-1614.

Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. (2002) Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 20:3399-3408.

King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. (2002). Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 4:479-88.

2000:

Foldvari M. (2000). Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm Sci Tech Today 3:417-425.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). Vaccine delivery: lipid-based delivery systems. J Biotechnol 83:91-104.

Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.

Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. (2000). Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18:2203-2211.

Papp Z, Middleton DM, Rontved CM, Foldvari M, Gordon JR, Baca-Estrada ME. (2000). Transtracheal administration of interleukin-12 induces neutrophil responses in the murine lung. J Interferon Cytokine Res 20:191-196.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. (2000). Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18:1847-1854.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). Vaccine delivery: lipid-based delivery systems. J Biotechnol 83:91-104.

Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.

Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. (2000). Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18:2203-2211.

Papp Z, Middleton DM, Rontved CM, Foldvari M, Gordon JR, Baca-Estrada ME. (2000). Transtracheal administration of interleukin-12 induces neutrophil responses in the murine lung. J Interferon Cytokine Res 20:191-196.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. (2000). Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system. Vaccine 18:1847-1854.

1999:

Jaafari MR, Foldvari M. (1999). P0 protein mediated targeting of liposomes to melanoma cells with high level of ICAM-1 expression. J Drug Target 7:101-112.

Foldvari M. (1999) Novel delivery systems for biotechnology drugs: Recent progress toward improved therapies. Can J Clin Pharmacol 6:65-66.

Baca-Estrada ME, Foldvari M, Snider M. (1999). Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res 19:455-462.

Baca-Estrada ME, Foldvari M, Snider M. (1999). Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interferon Cytokine Res 19:455-462.

Babiuk LA, Lewis J, Suradhat S, Baca-Estrada M, Foldvari M, Babiuk S. (1999) Polynucleotide vaccines: potential for inducing immunity in animals. J Biotechnol 73: 131-140.

Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M. (1999). Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol Appl Biochem 30 (Pt 2):129-37.

1998:

Foldvari M, Jaafari MR, Mezei M, Mezei C. (1998) Targeting liposomes through immunoglobulin superfamily domains: Po protein as model. Drug Deliv 5:183-195.

Foldvari M. (1998) Liposomal delivery systems in modern medicine. Drugs (Gyogyszereink) 48:162-171.

Foldvari M, Attah-Poku S, Hu J, Li Q, Hughes H, Babiuk LA, Kruger S. (1998). Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery (PDF). J Pharm Sci 87:1203-1208.

1997:

Baca-Estrada ME, Foldvari M, Snider M, van Drunen Littel-van den Hurk S, Babiuk LA. (1997). Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. Vaccine 15:1753-1760.

Baca-Estrada ME, Foldvari M, Snider M, van Drunen Littel-van den Hurk S, Babiuk LA. (1997). Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. Vaccine 15:1753-1760.